Aerovate Therapeutics Inc... (AVTE)
2.75
-0.02 (-0.72%)
At close: Apr 22, 2025, 3:59 PM
2.75
0.00%
Pre-market: Apr 23, 2025, 07:34 AM EDT
-0.72% (1D)
| Bid | 2.74 |
| Market Cap | 79.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.63M |
| EPS (ttm) | -2.44 |
| PE Ratio (ttm) | -1.13 |
| Forward PE | -3.54 |
| Analyst | Hold |
| Ask | 2.8 |
| Volume | 934,168 |
| Avg. Volume (20D) | 148,281 |
| Open | 2.80 |
| Previous Close | 2.77 |
| Day's Range | 2.74 - 2.85 |
| 52-Week Range | 1.25 - 25.29 |
| Beta | 0.95 |
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 30
Stock Exchange NASDAQ
Ticker Symbol AVTE
Website https://aerovatetx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $2, which is a decrease of -27.27% from the latest price.
Stock Forecasts5 months ago
+11.87%
Aerovate Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
9 months ago
+8.07%
Aerovate Therapeutics shares are trading higher after the company announced it is exploring strategic alternatives.
